SOLANO
A Randomized, Parallel, Double-Blind, Placebo-Controlled Phase 2b Study to Assess the Safety, Efficacy and Tolerability of AZD8233 Treatment in Participants with Hyperlipidaemia
- Stadium
- klaar
- Middel
- AZD8233 (subcutaan PCSK9-i)
- Populatie
- ASCVD
- Fase
- II
- First Patient In
- 13 september 2021
- Last Patient In
- 6 oktober 2021
- Last Patient Last Visit
- 14 juli 2022
National Lead
prof. dr. E.S.G. Stroes
Cardioloog
Studiedirecteur
dr. M.W.J. van Hessen
Cardioloog
Contact Kantoor
